Abstract
Aims/hypothesis The aim of this study was to evaluate the impact on metabolic control of the periodic use of a 5-day fasting-mimicking diet (FMD) program as an adjunct to usual care in people with type 2 diabetes under regular primary care surveillance.
Methods In this randomised, controlled, assessor-blinded trial, people with type 2 diabetes using metformin only and/or diet alone for glycaemic control were randomised to receive 5-day cycles of FMD monthly as adjunct to regular care by their general practitioner or regular care only. Primary outcomes were changes in glucose-lowering medication and HbA1c levels after 12 months. Moreover, changes in use of glucose-lowering medication and/or HbA1c levels in individual participants were combined to yield a clinically relevant primary outcome measure (‘glycaemic management’), categorized as improved, stable or deteriorated after one year of follow-up.
Results 100 individuals with type 2 diabetes, age 18-75 years, and BMI > 27 kg/m2, were randomised to the FMD (n=51) or control group (n=49). Eight FMD participants and ten controls were lost to follow-up. In complete case intention-to-treat analyses, the mean medication effect score (MES) significantly declined in patients receiving FMD as compared to controls (FMD −0.2 ± 0.3 vs controls +0.2 ± 0.4, p<0.0001) in the face of similar changes of HbA1c adjusted for MES (FMD −0.4 ± 0.8 % vs controls +0.2 ± 0.8 %, p=0.0021). Glycaemic management improved in 53% of participants using FMD vs 8% of controls, remained stable in 23% vs 33%, and deteriorated in 23% vs 59% (p<0.0001).
Conclusions/interpretation Integration of a monthly FMD program in regular primary care for people with type 2 diabetes who use metformin only and/or diet alone for glycaemic control reduces the need for glucose-lowering medication and appears to be safe in routine clinical practice.
Trial registration ClinicalTrials.gov: NCT03811587
Competing Interest Statement
Financial support was received from Health∼Holland, Top Sector Life Sciences & Health, the Dutch Diabetes Foundation, and L-Nutra for the project; VL is founder and shareholder of L-Nutra (his shares are destined to the Create Cures Foundation and other charitable and research organizations), owns patents licensed to L-Nutra, receives support for travel expenses from L-Nutra and is on the advisory board of L-Nutra; HL has received consulting fees from Royal Philips and was member of the board of trustees of the SCMR and UEMS section Radiology without payment; no other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
NCT03811587
Clinical Protocols
https://doi.org/10.1186/s12902-020-00576-7
Funding Statement
The project was co-funded by Health∼Holland, Top Sector Life Sciences & Health, and the Dutch Diabetes Foundation. L-Nutra contributed the formula diet and a small part of the funding. External peer-review took place during the funding process and was performed by ZonMw (The Netherlands Organisation for Health Research and Development). The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, approval of the manuscript or the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Leiden University Medical Centre gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed in the current study are available upon reasonable request. Requests should be sent to the FIT trial corresponding email (fit{at}lumc.nl). All proposals requesting data access will need to specify how the data will be used, and all proposals will need approval of the trial co-investigator team before data release.
